CD19 and diffuse large B-cell lymphoma: The correlation of the CD19 L174 variant and a favorable outcome in the observed DLBCL cohort is in accordance with a recent study, where lymphoma cells with a somatic mutation encoding CD19 V174 were reported to show insufficient response to FMC63-CAR19-T cell therapy compared to CD19 L174 lymphoma cells [26].